|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008059,
umls-concept:C0008976,
umls-concept:C0012634,
umls-concept:C0032150,
umls-concept:C0032339,
umls-concept:C0206255,
umls-concept:C0231449,
umls-concept:C1510693,
umls-concept:C1522577,
umls-concept:C1539358,
umls-concept:C1545588,
umls-concept:C1708528,
umls-concept:C2587213,
umls-concept:C2926735
|
|
pubmed:issue |
9502
|
|
pubmed:dateCreated |
2005-12-12
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
RTS,S/AS02A is a pre-erythrocytic stage malaria vaccine that provides partial protection against infection in malaria-naive adult volunteers and hyperimmune adults. A previous report showed that this vaccine reduced risk of clinical malaria, delayed time to new infection, and reduced episodes of severe malaria over 6 months in African children. An important remaining issue is the durability of protection against clinical disease in these children.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1474-547X
|
|
pubmed:author |
pubmed-author:AidePedroP,
pubmed-author:AlonsoPedro LPL,
pubmed-author:AponteJohn JJJ,
pubmed-author:BallouW RipleyWR,
pubmed-author:BassatQuiqueQ,
pubmed-author:CohenJoeJ,
pubmed-author:CorachanSabineS,
pubmed-author:DuboisMarie-ClaudeMC,
pubmed-author:DubovskyFilipF,
pubmed-author:EspasaMateuM,
pubmed-author:GuinovartCaterinaC,
pubmed-author:LeachAmandaA,
pubmed-author:LievensMarcM,
pubmed-author:MaceteEusebioE,
pubmed-author:MandomandoInacioI,
pubmed-author:MenendezClaraC,
pubmed-author:MilmanJessicaJ,
pubmed-author:NaviaMargarita MMM,
pubmed-author:SacarlalJahitJ,
pubmed-author:SigauqueBetuelB,
pubmed-author:ThompsonRicardoR
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
10
|
|
pubmed:volume |
366
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2012-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16338450-Animals,
pubmed-meshheading:16338450-Antibodies, Protozoan,
pubmed-meshheading:16338450-Child, Preschool,
pubmed-meshheading:16338450-Cross-Sectional Studies,
pubmed-meshheading:16338450-Follow-Up Studies,
pubmed-meshheading:16338450-Humans,
pubmed-meshheading:16338450-Infant,
pubmed-meshheading:16338450-Malaria, Falciparum,
pubmed-meshheading:16338450-Malaria Vaccines,
pubmed-meshheading:16338450-Mozambique,
pubmed-meshheading:16338450-Plasmodium falciparum,
pubmed-meshheading:16338450-Severity of Illness Index,
pubmed-meshheading:16338450-Single-Blind Method
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial.
|
|
pubmed:affiliation |
Centre de Salut Internacional, Hospital Clínic/ Institut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Villarroel 170, 08036 Barcelona, Spain. palonso@clinic.ub.es
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
